Results 21 to 30 of about 21,990 (200)

Assessment and development of adenovirus type 11 for cancer therapy [PDF]

open access: yes, 2010
PhDThe efficacy of oncolytic virotherapy is influenced by the interactions between the tumour, virus and host immunity. The first generation of oncolytic adenoviruses, based on serotype 5 (Ad5), has achieved limited success in clinical trials.
Wong, Han Hsi
core   +4 more sources

Advances in oncolytic virotherapy

open access: yesCommunications Medicine, 2022
Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers. There are challenges to address, however, if we are to maximize the impact of these therapies in patients.
Stephen J. Russell   +3 more
openaire   +3 more sources

Personalizing Oncolytic Virotherapy

open access: yesHuman Gene Therapy, 2023
The use of oncolytic viruses has become an attractive tool in the clinics for the treatment of various tumor types. Such viruses are genetically modified to conditionally replicate in malignant cells while unharming healthy cells. This platform offers a highly specific tumor killing with exceptional safety profiles.
Firas Hamdan   +2 more
openaire   +4 more sources

Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?

open access: yesCancer Cell International, 2022
Viruses are completely dependent on host cell machinery for their reproduction. As a result, factors that influence the state of cells, such as signaling pathways and gene expression, could determine the outcome of viral pathogenicity.
Sara Shayan   +2 more
doaj   +1 more source

Cytokines in oncolytic virotherapy

open access: yesCytokine & Growth Factor Reviews, 2020
Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail ...
Pol, Jonathan   +4 more
openaire   +3 more sources

Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

open access: yesMolecular Therapy: Oncolytics, 2022
Oncolytic viruses are designed to specifically target cancer cells, sparing normal cells. Although numerous studies demonstrate the ability of oncolytic viruses to infect a wide range of non-tumor cells, the significance of this phenomenon for cancer ...
Victor A. Naumenko   +4 more
doaj   +1 more source

Oncolytic Virotherapy Trials—Letter [PDF]

open access: yesClinical Cancer Research, 2013
We would like to thank Prof. Harrington for his insightful commentary ([1][1]) regarding our article by Kanerva and colleagues ([2][2]). During 2007–2011, the Advanced Therapy Access Program (ATAP) provided a unique opportunity for patients to access a technology they would not otherwise have ...
Hemminki Akseli   +3 more
openaire   +2 more sources

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity

open access: yesMolecular Therapy: Oncolytics, 2022
Oncolytic virotherapies have shown excellent promise in a variety of cancers by promoting antitumor immunity. However, the effects of oncolytic virus-mediated type I interferon (IFN-I) production on antitumor immunity remain unclear.
Nader El-Sayes   +6 more
doaj   +1 more source

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect [PDF]

open access: yes, 2017
: With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits.

core   +1 more source

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

open access: yesMolecular Cancer, 2020
As a promising therapeutic strategy, oncolytic virotherapy has shown potent anticancer efficacy in numerous pre-clinical and clinical trials. Oncolytic viruses have the capacity for conditional-replication within carcinoma cells leading to cell death via
Bin Zhang, Ping Cheng
doaj   +1 more source

Home - About - Disclaimer - Privacy